Skip to content

QuarterlyIQ Insights · LLY

Factors

The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.

Factor signals

Each factor is a parallel diagnostic with a plain-language read of what it shows and how names like it have historically fared. Never aggregated into a single score.

Recent financial performance
strong

Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).

86th pctl · Health Care
The numbers
bonus
0
dir share
1
slope norm
0.0932
Earnings quality
fragile

Over the trailing year it converted 0.81x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).

8th pctl · Health Care
The numbers
ttm ni
25277
ttm cfo
20480
Macro sensitivity

Most sensitive to the broad stock market.

  • the broad stock market: This stock moves with the broad market (high beta).β 0.62 · R² 0.08

Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).

Management & capital allocation
stable

2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).

76th pctl · Health Care
The numbers
n events
2
raw activity
0.2707
directional rank
0.6008
directional status
neutral

Not investment advice. As of 2026-06-09.

Earnings setup & market context

The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.

Earnings setup · pre-print positioning
forward-looking
bullish strong20 analysts, 77% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions

EPS estimate $8.75 → $8.81 (+0.7% / 30d). 18 raised, 1 cut, 20 covering analysts.

Rating actions

0 upgrades, 0 downgrades / 30d, 1 maintained. 77% of analysts rate Buy.

Price target activity

3 PT revisions / 30d. Avg target 17.5% above current price.

Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.

Sector context
Intermediate · Weekly
Sector phase: health care is in growth, with decelerating (~2.5 years in phase).
Sector regime (90d momentum): headwind.
headwind-9.2%sector vs S&P 500, 60d

via XLV

Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.

Full health care context →All sectors →

AI cycle regime · market-wide
2-axis classifierLong-term · 1–3 yr
HeatingManiaSquallCrisisEarnings →Mood ↑
HeatingE -0.23 · M +0.31
Single-axisneutralz +0.26

Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.

Not investment advice. As of 2026-06-09.